You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

MIDOL LIQUID GELS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Midol Liquid Gels patents expire, and what generic alternatives are available?

Midol Liquid Gels is a drug marketed by Bionpharma and is included in one NDA.

The generic ingredient in MIDOL LIQUID GELS is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Midol Liquid Gels

A generic version of MIDOL LIQUID GELS was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MIDOL LIQUID GELS?
  • What are the global sales for MIDOL LIQUID GELS?
  • What is Average Wholesale Price for MIDOL LIQUID GELS?
Summary for MIDOL LIQUID GELS
Drug patent expirations by year for MIDOL LIQUID GELS
Recent Clinical Trials for MIDOL LIQUID GELS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jerry Vockley, MD, PhDPhase 2
Ultragenyx Pharmaceutical IncPhase 2
University of California, San FranciscoPhase 4

See all MIDOL LIQUID GELS clinical trials

US Patents and Regulatory Information for MIDOL LIQUID GELS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma MIDOL LIQUID GELS ibuprofen CAPSULE;ORAL 021472-001 Oct 18, 2002 OTC Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for MIDOL LIQUID GELS

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for MIDOL LIQUID GELS

See the table below for patents covering MIDOL LIQUID GELS around the world.

Country Patent Number Title Estimated Expiration
Canada 2382292 GELS MOUS CONTENANT DE L'IBUPROFENE (IBUPROFEN-CONTAINING SOFTGELS) ⤷  Subscribe
Austria 357229 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 0115688 ⤷  Subscribe
Australia 780212 ⤷  Subscribe
Germany 60034044 ⤷  Subscribe
Poland 362850 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MIDOL LIQUID GELS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1781277 PA2024501 Lithuania ⤷  Subscribe PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

MIDOL LIQUID GELS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Midol Liquid Gels

Introduction to Midol Liquid Gels

Midol Liquid Gels, part of the Midol product line, are designed to provide fast and effective relief from various menstrual symptoms. These liquid-filled capsules contain naproxen sodium, a potent pain reliever, to tackle menstrual cramps, headaches, backache, and muscle pain.

Market Demand and Consumer Needs

The market demand for menstrual pain relief products is driven by the widespread need for effective solutions to manage period symptoms. Millions of women experience menstrual cramps, bloating, fatigue, and other associated discomforts each month. Midol Liquid Gels, with their fast-acting and long-lasting relief, cater to this significant consumer need.

Competitive Landscape

The menstrual pain relief market is competitive, with several brands offering various formulations. Midol, however, stands out due to its comprehensive symptom relief and the convenience of its products. Competitors include other over-the-counter (OTC) pain relievers and prescription medications, but Midol's multi-symptom approach gives it a unique market position.

Product Features and Benefits

  • Active Ingredients: Midol Liquid Gels contain naproxen sodium, which provides up to 12 hours of relief from menstrual cramps, headaches, backache, and muscle pain[3].
  • Convenience: Available in easy-to-take liquid-filled capsules, these gels are designed for quick absorption and long-lasting relief.
  • Multi-Symptom Relief: Unlike some competitors that focus solely on pain relief, Midol Liquid Gels address a range of symptoms including bloating, fatigue, and water-weight gain, although these are more prominently addressed in the Midol Complete formula[2][4].

Target Market

The primary target market for Midol Liquid Gels includes women of reproductive age, particularly those experiencing severe menstrual symptoms. This demographic is broad, encompassing women from various socioeconomic backgrounds and age groups, with a focus on those aged 12 to 65 years[3].

Marketing Strategies

Midol employs several marketing strategies to maintain its market presence:

  • Convenience Packaging: Midol offers on-the-go packaging options, such as the Midol Complete On-the-Go pouches, which are smaller than a phone and easy to carry. While this is more specific to Midol Complete, the convenience aspect is a selling point for all Midol products[5].
  • Brand Awareness: Midol invests in advertising and promotional campaigns to raise awareness about its products and their benefits.
  • Healthcare Professional Recommendations: Midol works with healthcare professionals to recommend its products, enhancing credibility and trust among consumers.

Financial Performance

The financial performance of Midol Liquid Gels is influenced by several factors:

  • Sales Volume: The demand for menstrual pain relief products is consistent, contributing to steady sales volumes.
  • Market Share: Midol's strong brand presence and comprehensive product line help maintain a significant market share in the OTC pain relief segment.
  • Revenue Growth: The convenience and effectiveness of Midol Liquid Gels contribute to revenue growth, especially as more women seek reliable and long-lasting relief from menstrual symptoms.

Pricing Strategy

Midol Liquid Gels are generally priced competitively within the OTC pain relief market. The pricing strategy is designed to balance profitability with consumer affordability, ensuring that the product remains accessible to a wide range of consumers.

Distribution Channels

Midol products, including the Liquid Gels, are widely available through various distribution channels:

  • Retail Pharmacies: Major retail pharmacies like Rite Aid, CVS, and Walgreens carry Midol products.
  • Online Retailers: Midol products are also available on online platforms such as Amazon and the company's official website.
  • Healthcare Providers: Recommendations from healthcare providers can drive sales through prescription or over-the-counter purchases.

Regulatory Environment

The regulatory environment for OTC pain relievers is stringent, with products needing to comply with FDA guidelines. Midol Liquid Gels, containing naproxen sodium, must adhere to these regulations to ensure safety and efficacy.

Consumer Feedback and Satisfaction

Consumer feedback is crucial for the ongoing success of Midol Liquid Gels. Positive reviews and recommendations from satisfied users help build brand loyalty and attract new customers. For example:

"Midol Liquid Gels have been a game-changer for me. The relief from menstrual cramps is almost immediate and lasts for hours." - Consumer Review

Innovation and Product Development

Midol continues to innovate and expand its product line to meet evolving consumer needs. This includes introducing new formulations and packaging options that enhance convenience and effectiveness.

Key Takeaways

  • Strong Market Demand: The consistent need for menstrual pain relief drives demand for Midol Liquid Gels.
  • Competitive Advantage: Midol's multi-symptom relief and long-lasting action give it a competitive edge.
  • Effective Marketing: Convenience packaging and healthcare professional recommendations are key marketing strategies.
  • Financial Stability: Steady sales volumes and competitive pricing contribute to financial stability.
  • Consumer Satisfaction: Positive consumer feedback is essential for brand loyalty and growth.

Frequently Asked Questions (FAQs)

Q: What are the active ingredients in Midol Liquid Gels? A: Midol Liquid Gels contain naproxen sodium, a potent pain reliever.

Q: How long does the relief from Midol Liquid Gels last? A: Midol Liquid Gels provide up to 12 hours of relief from menstrual symptoms.

Q: Are Midol Liquid Gels suitable for children? A: Yes, Midol Liquid Gels are recommended for both adults and children aged 12 years and older.

Q: Where can I purchase Midol Liquid Gels? A: Midol Liquid Gels are available at retail pharmacies, online retailers, and the company's official website.

Q: Do Midol Liquid Gels relieve symptoms other than pain? A: While Midol Liquid Gels primarily focus on pain relief, the broader Midol product line, such as Midol Complete, addresses additional symptoms like bloating, fatigue, and water-weight gain.

Cited Sources:

  1. Rite Aid - Midol Complete Multi-Symptom Relief, Maximum Strength, Gelcaps.
  2. Midol - Midol Complete.
  3. Midol - Maxidol Liquid Gels.
  4. Midol - Midol Complete.
  5. Midol - Midol On the Go Relief.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.